37675-20-0

Basic information

• Product Name: 3(R)-PIPERIDINEMETHANOL
• Synonyms: 3(R)-PIPERIDINEMETHANOL;((R)-piperidin-3-yl)methanol;2,4-diiodo-6-fluoroaniline;(3R)-piperidin-3-ylMethanol;3-PiperidineMethanol,(3R)-;(R)-(+)-3-(Hydroxymethyl)piperidine;(3R)-3-Piperidinemethanol
• CAS NO: 37675-20-0
• Molecular Formula: C₆H₁₃NO
• Molecular Weight: 115.17352
• Mol File: 37675-20-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 240.4°C at 760 mmHg
• Flash Point: 92.3°C
• Appearance: /
• Density: 0.951g/cm³
• Vapor Pressure: 0.00664mmHg at 25°C
• Refractive Index: 1.451
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 14.93±0.10(Predicted)
• CAS DataBase Reference: 3(R)-PIPERIDINEMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3(R)-PIPERIDINEMETHANOL(37675-20-0)
• EPA Substance Registry System: 3(R)-PIPERIDINEMETHANOL(37675-20-0)

Safety Data

• Hazardous Substances Data: 37675-20-0(Hazardous Substances Data)

Usage

General Description

3(R)-piperidinemethanol is a chemical compound with the molecular formula C6H13NO. It is a chiral amino alcohol that is often used as a building block in organic synthesis and pharmaceutical research. The "3(R)" designation indicates the position of the hydroxyl group on the piperidine ring, making it a specific enantiomer of the compound. 3(R)-PIPERIDINEMETHANOL has been studied for its potential applications in the development of new drugs and chemical reactions. Its unique structure and properties make it an important intermediate in the production of various pharmaceuticals and organic compounds.

InChI:InChI=1/C6H13NO/c8-5-6-2-1-3-7-4-6/h6-8H,1-5H2/t6-/m1/s1

Upstream product

• 37675-18-6 (S)-(+)-nipecotic acid ethyl ester 
• 71962-74-8 Ethyl nipecotate 
• 851956-01-9 (S)-(+)-3-piperidinecarboxylic acid hydrochloride 
• 498-95-3 (R)-nipecotic acid 
• 5621-43-2 diethyl 2-methyleneglutarate 
• 140645-20-1 t-butyl (R,S)-3-<(butyryloxy)methyl>-1-piperidine-carboxylate 
• 175694-36-7 (3R,5S)-Piperidine-1,3,5-tricarboxylic acid 1-benzyl ester 3-methyl ester 
• 88466-73-3 Z-β²hPro-OMe 
• 1221818-73-0 (3S,5R)-Piperidine-1,3,5-tricarboxylic acid benzyl ester dimethyl ester 
• 405061-52-1 N-Cbz-3-hydroxymethylpiperidine 
• 140695-84-7 tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate 

Downstream Products

• 140645-22-3 (3S)-3-azidomethyl-1-(tert-butoxycarbonyl)-piperidine 
• 140645-23-4 1,1-dimethylethyl (3R)-3-(aminomethyl)-1-piperidinecarboxylate 
• 1325233-13-3 2-amino-N-{((3R)-1-cyclohexylmethyl-3-piperidyl)methyl}acetamide 

Relevant articles and documents

Manganese Catalyzed Hydrogenation of Enantiomerically Pure Esters

A manganese-catalyzed hydrogenation of esters has been accomplished with TONs up to 1000, using cheap, environmentally benign, potassium carbonate and simple alcohols as activator and solvent, respectively. The weakly basic conditions lead to good functional group tolerance and enable the hydrogenation of enantiomerically enriched α-chiral esters with essentially no loss of stereochemical integrity.

Design, synthesis, and biological evaluation of simplified side chain hybrids of the potent actin binding polyketides rhizopodin and bistramide

The natural products rhizopodin and bistramide belong to an elite class of highly potent actin binding agents. They show powerful antiproliferative activities against a range of tumor cell lines, with IC50 values in the low-nanomolar range. At the molecular level they disrupt the actin cytoskeleton by binding specifically to a few critical sites of G-actin, resulting in actin filament stabilization. The important biological properties of rhizopodin and bistramide, coupled with their unique and intriguing molecular architectures, render them attractive compounds for further development. However, this is severely hampered by the structural complexity of these metabolites. We initiated an interdisciplinary approach at the interface between molecular modeling, organic synthesis, and chemical biology to support further biological applications. We also wanted to expand structure-activity relationship studies with the goal of accessing simplified analogues with potent biological properties. We report computational analyses of actin-inhibitor interactions involving molecular docking, validated on known actin binding ligands, that show a close match between the crystal and modeled structures. Based on these results, the ligand shape was simplified, and more readily accessible rhizopodin-bistramide mimetics were designed. A flexible and modular strategy was applied for the synthesis of these compounds, enabling diverse access to dramatically simplified rhizopodin-bistramide hybrids. This novel analogue class was analyzed for its antiproliferative and actin binding properties.

FARNESYL PROTEIN TRANSFERASE INHIBITORS

Disclosed are compounds of formula (1.0), wherein R represents a cyclic moiety to which is bound an imodazolylalkyl group; R represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.